Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci official news RSS · 行業原文收錄 · 來源發佈：Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。